FDA approves new competitor to $2.1million drug for SMA
Aug 11, 2020 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
Several manufacturers of metformin ER have been asked to voluntarily recall their metformin ER products by the FDA. Laboratory tests have revealed high levels of the nitrosamine impurity N-Nitrosodimethylamine (NDMA), which may increase the risk of cancer if consumed at high-doses for a long period of time.
FDA recalls several metformin ER products for diabetes
Jun 9, 2020 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
Several manufacturers of metformin ER have been asked to voluntarily recall their metformin ER products by the FDA. Laboratory tests have revealed high levels of the nitrosamine impurity N-Nitrosodimethylamine (NDMA), which may increase the risk of cancer if consumed at high-doses for a long period of time.
COVID-19 challenges us to adapt to a 'new normal'.
Mar 30, 2020 |
Trends, Insights & Analysis,
News,
Pharmaceutical Manufacturers,
Consumers,
Pharmacy Benefit Managers
COVID-19 challenges to us adapt to a 'new normal' and problem-solve for the future. What does this mean for you?
Managing through COVID-19 as a plan sponsor
Mar 6, 2020 |
Trends, Insights & Analysis,
News,
Consumers
As the U.S. prepares for the spread of COVID-19, plan sponsors may be questioning if there is anything that they need to do with their pharmacy benefit.
Weight-Loss Drug Withdrawn from Market Due to Cancer Risk
Feb 19, 2020 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
Eisai Inc. announced that under the recommendation of the FDA, it will voluntarily withdraw Belviq and Belviq XR from the market due to concerns about a possible increased risk of cancer.
New Migraine Treatments Promise Relief But Costs May Be Concerning
Feb 19, 2020 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
It looks like 2020 will be a big year for migraine sufferers. In the fall of 2019, the FDA approved Eli Lilly’s Reyvow for the acute (immediate) treatment of migraines. This is the first FDA-approved drug in a new class of acute migraine treatments that is taken orally as needed when a migraine occurs.
Drug Pricing Transparency Legislation Updates
Feb 6, 2020 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
There has been a growing clamor among a wide range of healthcare and policy stakeholders for drug pricing transparency and pharmacy spend cost containment.
Free Access to PrEP Drugs Promising for HIV Reduction; May Later Impact Pharmacy Benefit Plans
Jan 23, 2020 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
Gilead, the Big 3 retail pharmacy chains (CVS, Walgreens, Rite Aid), and the Department of Health & Human Services (HHS) recently announced their collaboration to offer free HIV Pre-exposure prophylaxis (PrEP) medications to consumers with no health insurance.
New Breakthrough Cystic Fibrosis Drug Promising for Patients, Challenging for Benefit Plans
Dec 9, 2019 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
The FDA has announced the approval of Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy to treat the most common form of cystic fibrosis. This new drug has the cystic fibrosis (CF) community excited because it is expected to treat 90% of the CF population.
Peanut Allergy Drug Inches Closer to FDA Approval
Dec 4, 2019 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
Aimmune Therapeutics' peanut allergy treatment, Palforzia, has passed the FDA's advisory committee review. The committee voted 7 to 2 in favor of the drug's effectiveness and 8 to 1 on safety but concerns about the drug’s effectiveness remain.
New Oral Diabetes Drug May Replace Injectables
Sep 20, 2019 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers
Novo Nordisk’s Rybelsus was FDA approved today and it is expected to stir up the diabetes market. This is the first oral tablet formulation of semaglutide, which may be better known to you as Ozempic from all the TV commercials with the catchy jingle.
HHS Proposes Action Plan to Import Foreign Prescription Drugs
Aug 30, 2019 |
Trends, Insights & Analysis,
News,
Prescription Drug News & Regulations - Employers
The US Department of Health and Human Services (HHS) has announced a plan to lower drug costs by importing prescription drugs intended for sale in foreign markets.
A Busy Month in Washington - Drug News of Note July 2019
Jul 30, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest drug news, FDA approvals, and regulations. This month, we highlight the Senate's proposal for an inflation-based drug pricing cap, HHS withdrawing its proposal to eliminate rebates for Part D and Medicaid managed care, and HHS' proposed rule for WAC disclosure on advertising hits a snag.
Truveris Featured in Managed Care Magazine's Innovation Issue
Jul 12, 2019 |
Trends, Insights & Analysis
In a piece titled, Reverse Auction Grows PBM Savings for the Garden State, Managed Care Magazine highlighted the story of how Truveris' reverse-auction pharmacy benefit procurement solution helped the State of New Jersey save more than $1 billion and how it may be a model for other states looking to reduce their pharmacy benefit spend.
What we learned from the Amazon PillPack and CVS Caremark Lawsuit - Drug News of Note June 2019
Jun 27, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest drug news, FDA approvals, and regulations. This month, we highlight the CVS Caremark / PillPack non compete, the international pricing index, and the FDA's new opioid approval process.
HHS Requires List Price to Be Included in TV Drug Advertisements - Drug News of Note May 2019
May 31, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations. This month, we highlight HHS requirement that list price be included in TV ads, FDA approval of Zolgensma, and Gilead Sciences agreement to donate PrEP medications to a government effort to reduce HIV rates.
Prescription Drug News of Note - April 2019
May 1, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations. This month, we highlight CMS' targeting of manufacturer coupons, Sanofi's launching of a flat fee program for insulins, and Amazon's initial marketing of PillPack to Amazon Prime members
Prescription Drug News of Note - March 2019
Mar 29, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations. This month, we highlight news of Louisiana's new Hepatitis C cost containment program, Eli Lilly's new authorized generic insulin, and the FDA's approval of a new Diovan generic.
Truveris Wins 2019 PBMI Excellence Award for Cost Containment
Mar 6, 2019 |
Trends, Insights & Analysis
The Pharmacy Benefit Management Institute (PBMI) announced Truveris as the winner of its 2019 Excellence Award for Cost Containment.
The Excellence Award in Cost Containment was given for TruGuard, the Truveris solution for PBM contract oversight and continuous monitoring.
Prescription Drug News of Note - February 2019
Feb 28, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations. This month, we have an update on the NASH pipeline, notify on a black box warning for Uloric, a gout medication, and an update on HHS blocking drug rebates for government sponsored plans
Anthem to Transition Members to IngenioRx PBM 10 Months Sooner Than Expected
Feb 6, 2019 |
Trends, Insights & Analysis,
Drug Pricing,
Prescription Drug News & Regulations - Employers,
Pharmacy Benefit Managers
Expectations were for the new PBM to launch in 2020, but Anthem recently announced that they are accelerating the launch of IngenioRx and expect to begin transitioning members by the second quarter of 2019. This transition is starting 10 months sooner than the industry expected.
HHS Proposes Rule to Change Anti Kickback Laws
Feb 5, 2019 |
Trends, Insights & Analysis,
Drug Pricing,
Prescription Drug News & Regulations - Employers,
Pharmacy Benefit Managers
On January 31st, the Department of Health and Human Services (HHS) proposed major changes to the federal Anti-Kickback Statute that If passed, will bring a new level of transparency to PBM contracting.
Prescription Drug News of Note - January 2019
Jan 31, 2019 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Updated Management Guidelines for AFib |
Cancer Rates Continue to Fall | Increased Spending Within Type 1 Diabetes
Prescription Drug News of Note - December 2018
Dec 30, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Oncology biosimilars approved by FDA |
Guidance on NASH medication development | January price increases
Prescription Drug News of Note - November 2018
Nov 30, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Generic for MS |
New recommendations on HIV therapy | FDA approves new cancer medication with a unique indication
It’s Never Too Early to Take Your Pharmacy Benefit Out to Bid
Nov 29, 2018 |
Trends, Insights & Analysis,
Pharmacy Carve Out,
Pharmacy Benefit Managers
Maximizing the value of your pharmacy benefit takes a lot of runway, especially for larger organizations. The sooner a decision is made, the better prepared your employees will be for any potential changes. And if Jan. 1, 2020 is your target date to enact new plans, now is the time start working toward that.
Prescription Drug News of Note - October 2018
Oct 30, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Cholesterol drug price reduction?!
New FDA approval on a flu treatment | Comparative results of two MS products | FDA expands indication for Hemophilia medication
Prescription Drug News of Note - September 2018
Oct 1, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: This month includes figures on the prevalence of Diabetes among US adults, new Migraine management products, Vascepa showing reduction in cardiovascular events, and new Hepatitis C generics,.
Prescription Drug News of Note - August 2018
Aug 29, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: This month includes news on FDA approval of a first-of-its-kind peripheral nerve disease (polyneuropathy) therapy, and the latest on Teva's EpiPen generic
Prescription Drug News of Note - July 2018
Jul 31, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: This month includes news on FDA approval of Tibsovo and Nivestym, and highlights positive results from an Alzheimer's trial
How to Make Smarter Decisions About Your Company’s Prescription Drug Spend
Jul 11, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Pharmacy Benefit Managers
As pharmacy benefit costs continue to rise, effective PBM management is needed more than ever. TruBid brings transparency and savings to today’s companies.
Prescription Drug News of Note - June 2018
Jun 29, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: This month includes news on FDA approval of marijuana-based seizure medication, thoughts on whether OLUMIANT change inflammatory drug pricing, an analysis of Part D spending on brand drugs, and last but not least, Amazon's acquisition of PillPack.
Prescription Drug News of Note - May 2018
May 31, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Positive clinical results for Praulent, more M&A activity with Cigna and Express Scripts, and the recent JAMA study on US Healthcare Spending
Prescription Drug News of Note - April 2018
Apr 27, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Positive clinical results for Praulent, more M&A activity with Cigna and Express Scripts, and the recent JAMA study on US Healthcare Spending
4 Ways to Tell a Copay Program Vendor from a Copay Program Partner
Apr 16, 2018 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs,
Patient Access Programs
Who's at the table for your brand planning sessions?
What Princess Is Your Copay Program?
Apr 3, 2018 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs,
Patient Access Programs
If your copay program is underwater, it might be Ariel.
Making Sense of Benefit M&A
Mar 29, 2018 |
Trends, Insights & Analysis,
Prescription Drug News & Regulations - Employers,
Pharmacy Benefit Managers
With recent mergers like the Cigna/Express Scripts (ESI) deal, stakeholders across the pharmaceutical industry are curious about the future of independent PBMs, the future of pharmacy carve-out, the opportunity for Truveris, and if/how Amazon can be a catalyst to a major change in the way that we experience, and pay for, healthcare.
Prescription Drug News of Note - March 2018
Mar 27, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: Positive clinical results for Praulent, more M&A activity with Cigna and Express Scripts, and the recent JAMA study on US Healthcare Spending
Prescription Drug News of Note - February 2018
Feb 27, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: FDA Approvals, Prescription spending trends, and the latest on Albertson's and Rite Aid
Deductibles and the Consumerization of Healthcare: What Does it Mean for Biopharma Brands?
Feb 7, 2018 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Patient Access Programs
As consumers are gaining more control over their healthcare spend, here’s what biopharma brands need to consider.
2018 Specialty Drug Trends: What Employers Should Expect
Jan 30, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Pharmacy Benefit Managers
Specialty drugs are expensive for employers paying for prescription benefit plans. Learn how to lower costs in 2018 with specialty drug management strategies.
Prescription Drug News of Note - January 2018
Jan 26, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations: FDA Approves 46 Novel Medications in 2017, Hospitals to Start Their Own Generic Drug Company
Is Cutting Costs on Your Copay Program Costing You?
Jan 22, 2018 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
The long term costs of your copay program’s patient benefit often outweigh the upfront costs of program administrative fees. Here’s what to watch out for.
PBM Contracts: 7 Terms Employers Need to Know
Jan 12, 2018 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Pharmacy Benefit Managers
PBM contracts can be confusing and packed with jargon. Here’s what employers need to know to navigate their pharmacy benefits.
5 Dos and Don’ts in Your New Copay Program’s First Weeks
Jan 5, 2018 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
The new year means a new copay program for many brand managers. Here are a few things to think about as you watch the results from your copay program come in.
Your Cheat Sheet for Pharmacy Benefits
Dec 26, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Pharmacy Benefit Managers
Pharmacy benefits can be confusing, with many moving parts. Our cheat sheet breaks down what you need to know to become wiser in the area of pharmacy benefits.
Top 4 Myths of Pharmacy Benefits
Dec 26, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Pharmacy Benefit Managers
When it comes to pharmacy benefits, there's a lot of information out there — and a lot of misinformation. We present and debunk 4 myths about pharmacy benefits.
Prescription Drug News of Note - December 2017
Dec 25, 2017 |
Trends, Insights & Analysis
Each month, we round up the latest FDA approvals and regulations... FDA approves Lyrica CR capsules, Imprimis Pharmaceuticals announces alternative to Restasis
Six Best Practices for Working with Self-Insured Businesses
Dec 20, 2017 |
Trends, Insights & Analysis,
Brokers,
Pharmacy Benefit Managers
What advice can brokers give to their self-insured clients? Here are six best-practices for helping self-insured clients control costs and mitigate risk.
Why collecting patient data may be the best thing for your brand
Dec 18, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Patient Access Programs
When done correctly, collecting patient data can have a big impact on your brand. Here’s how to do it well.
Three Ways to Enhance Your Patient Engagement Strategy
Dec 12, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Patient Access Programs
Your pharmaceutical CRM has huge potential to drive patient engagement and lower abandonment rates. Targeted, timely messaging is the key to success.
Pharmacy Carve Out: Why it Makes Sense for Employers
Nov 28, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Brokers,
Pharmacy Carve Out
Thinking about carving out your company’s pharmacy benefits? Here’s why a pharmacy carve-out might be right for your company.
Prescription Drug News of Note - November 2017
Nov 28, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations... FDA approves Lyrica CR capsules, Imprimis Pharmaceuticals announces alternative to Restasis
3 Ways to Use Copay Program Data to Reach Physicians
Nov 20, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
Copay program data can help your brand succeed in the physician’s office. Learn more on the Truveris blog.
What is a Pharmacy Carve Out Plan?
Nov 14, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Brokers,
Pharmacy Carve Out
Employers are turning to pharmacy carve out plans as a solution to rising prescription drug costs. Here’s your primer on carving out pharmacy benefits.
Truveris Ranks on Deloitte's 2017 #Fast500 List of Fastest-Growing Technology Companies
Nov 9, 2017 |
Trends, Insights & Analysis
Deloitte announced that Truveris is one of the fastest growing technology companies in North America, reaching #205 on their annual Technology Fast 500 list.
Six Places Your Copay Program can Provide Deeper Insights and Drive Success
Oct 30, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
Your copay program is generating a wealth of data, but do you know how and where to use it?
What Anthem's new PBM, IngenioRx means for Brokers and Employers
Oct 23, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Pharmacy Benefit Managers
Anthem, Inc. announced that it is establishing a new pharmacy benefits manager (PBM) named IngenioRx. What does this mean for employers and brokers?
California’s Copay Coupon Bill Stirs Up Panic—Here’s What Pharmaceutical Brand Teams Need To Know.
Oct 16, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Prescription Drug News & Regulations - Pharma
How to navigate California's AB-265, a bill designed to curb the use of copay coupons for branded prescription drugs when a generic version is available.
Prescription Drug News of Note - October 2017
Oct 15, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations to give you an expert take on what you need to know.
Is Your Patient Abandonment Rate Really What You Think it is?
Oct 2, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Patient Abandonment
Determining your brand’s true patient abandonment rate starts with understanding the data from key steps along the patient journey.
How Artificial Intelligence in Healthcare is Helping Physicians Better Prescribe Treatments
Sep 21, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Medicine & Technology
The growing use of AI in healthcare is leading to more effective individualized treatments and greater patient access.
Prescription Drug News of Note - September 2017
Sep 11, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Prescription Drug News & Regulations - Employers
Each month, we round up the latest FDA approvals and regulations to give you an expert take on what you need to know.
Top 5 Copay Program Fallacies
Sep 8, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
There are many common misconceptions associated with designing or managing your copay program. Don’t be fooled by them, as they are likely hindering your performance.
Is Your Copay Program Ready For 2018?
Aug 24, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
It’s after Labor Day and you have spent the summer carefully brand planning and strategically evaluating the tactics you need to put in place for 2017.
Are You Considering The Right Segmentation Options For Your Copay Program?
Aug 24, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
When it comes to designing your copay program, chances are you haven’t considered all of the options.
What is a Pharmacy Benefit Manager (PBM) and how Does a PBM Impact the Pharmacy Benefits Ecosystem?
Aug 15, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Pharmacy Benefit Managers
Pharmacy Benefits Managers play an important and often complicated role in the prescription benefits industry. Learn more on the Truveris blog.
Is Your Copay Program Costing You More Than It’s Earning? Keep These Top 5 Metrics In Mind
Aug 11, 2017 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Copay Programs
While the strategy and goals of every copay program vary, we’ve found that the top 5 essential metrics to track ROI stay the same.
Prescription Drug News of Note – August 2017
Aug 1, 2017 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Prescription Drug News & Regulations - Employers
A rundown of the latest FDA approvals and regulations from August 2017, with an expert take on what you need to know in the prescription drug industry.
The Keys To A Successful Partnership
Dec 12, 2016 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Patient Access Programs
Use these five tips to create a productive relationship with your partner to ensure your copay program’s success.
The Single Question You Are Missing From Your RFP
Nov 16, 2016 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Patient Access Programs
Selecting the right strategic partner can be a challenge and a Request for Proposal (RFP) is an important part of the selection process.
How Can 340B Pricing Help Healthcare Organizations Save On Medications?
May 25, 2016 |
Trends, Insights & Analysis,
Pharmaceutical Manufacturers,
Prescription Drug News & Regulations - Pharma
As prescription drug prices continue to increase, consumers are finding it increasingly difficult to pay for their medications.
10 Questions Employers Should Be Asking About the Cadillac Tax
Apr 20, 2016 |
Trends, Insights & Analysis,
Enterprise Employers,
Prescription Drug News & Regulations - Employers
The Cadillac Tax is an excise tax levied on employers that provide high-cost health benefit plans to their employees.
What Is A Single Source Generic And How Does It Impact Drug Pricing?
Apr 7, 2016 |
Trends, Insights & Analysis,
Enterprise Employers,
Labor Unions,
State & Public Employers,
Brokers,
Drug Pricing
Before signing up for any new insurance plan, you should familiarize yourself with an often overlooked segment of insurance – your pharmacy benefits plan.
Exploring the Price of Medication
Mar 29, 2016 |
Trends, Insights & Analysis,
Consumers,
Drug Pricing
Drug prices have increased dramatically over the past decade. But only 17 percent of consumers shop around for drugs to see if they can get better deal.
How Do Genes Affect Drug Response?
Mar 16, 2016 |
Trends, Insights & Analysis,
Consumers,
Medicine & Technology
Have you ever wondered why some medications work for certain people but not others? Why might you experience side effects from a drug while your friend doesn’t?
3 Novel Ways Medication May Impact Your Health
Mar 1, 2016 |
Trends, Insights & Analysis,
Consumers,
Medicine & Technology
Drugs affect everyone differently. So when you’re prescribed a medication, what factors dictate how it will impact your health?